ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$3.74
0.01 (0.27%)
â˛
5d:
-3.86%
30d:
-2.09%
90d:
+21.43%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $3.74, which is considered fair relative to its 30-day fair value range of $3.25 to $4.08. From a valuation perspective, the stock is trading at a discount (Forward PE: -623.3) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a downtrend. The price is currently testing key support at $3.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACB scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.23 (+66.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACB is in a downtrend. The price is currently testing key support at $3.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ACB scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.23 (+66.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.25 -
$4.08
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.5% below Wall St target ($6.23)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.25 -
$4.08
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.68
Resistance Level
$4.15
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-623.33
Wall Street Target
$6.23
(+66.5%)
Revenue Growth (YoY)
-8.8%
Earnings Growth (YoY)
-94.7%
Profit Margin
-38.2%
PE vs Historical
-623.3 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: September 14, 2026 5:17 AM ET
Data refreshes hourly during market hours. Next update: 6:17 AM
Data refreshes hourly during market hours. Next update: 6:17 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
